| EDUCATIONAL FORUM |
|
| Year : 2012 | Volume
: 2
| Issue : 2 | Page : 77-83 |
|
|
Vaptans: A new option in the management of hyponatremia
Suruchi Aditya1, Aditya Rattan2
1 Department of Pharmacology, Dr. Harvansh Singh Judge Institute of Dental Sciences, Chandigarh, India
2 Consultant Cardiologist, Heartline, Panchkula, Haryana, India
Correspondence Address:
Suruchi Aditya
Department of Pharmacology, Dr. Harvansh Singh Judge Institute of Dental Sciences, Sector 25, Chandigarh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2229-516X.106347
|
|
|
Arginine vasopressin (AVP) plays an important role in water and sodium homeostasis. It acts via three receptor subtypes-V 1 a, V 1 b, and V 2 -distributed widely throughout the body. Vaptans are nonpeptide vasopressin receptor antagonists (VRA). By property of aquaresis, VRAs offer a novel therapy of water retention. Conivaptan is a V 1 a/V 2 nonselective VRA approved for euvolemic and hypervolemic hyponatremia. Tolvaptan is the first oral VRA. Other potential uses of this new class of drugs include congestive heart failure (CHF), cirrhosis of liver, syndrome of inappropriate secretion of antidiuretic hormone, polycystic kidney disease, and so on. These novel drugs score over diuretics as they are not associated with electrolyte abnormalities. Though much remains to be elucidated before the VRAs are applied clinically, the future holds much promise. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
